Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma

Cancer

Volumn 119, Issue 10, 2013, Pages 1860-1867

  Bagaria, Sanjay P ^a   Ray, Partha S ^b   Joseph, Richard W ^a   Heckman, Michael G ^a   Rawal, Bhupendra ^a   Gray, Richard J ^c   Pockaj, Barbara ^c   Wasif, Nabil ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c MAYO CLINIC   (United States)

Author keywords

biomarker; lymph node metastasis; melanoma; prognosis; tumor depth

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR CLASSIFICATION; TUMOR VOLUME; ULTRATHIN MELANOMA;

ADULT; AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PALPATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; UNITED STATES;

EID: 84877577038     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27985     Document Type: Article

References (20)

1. Breslow A,. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970; 172: 902-908.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27: 6199-6206.
3. Haddad FF, Stall A, Messina J, et al. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann Surg Oncol. 1999; 6: 144-149.
4. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH,. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991; 214: 491-499; discussion 499-501.
5. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003; 10: 569-574.
6. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010.
7. Green AC, Baade P, Coory M, Aitken JF, Smithers M,. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012; 30: 1462-1467.
8. Murali R, Haydu LE, Long GV, et al. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. Ann Surg Oncol. 2012; 19: 1782-1789.
9. Jemal A, Devesa SS, Hartge P, Tucker MA,. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001; 93: 678-683.
10. Faries MB, Wanek LA, Elashoff D, Wright BE, Morton DL,. Predictors of occult nodal metastasis in patients with thin melanoma. Arch Surg. 2010; 145: 137-142.
11. Garbe C, Leiter U,. Melanoma epidemiology and trends. Clin Dermatol. 2009; 27: 3-9.
12. McKinnon JG, Yu XQ, McCarthy WH, Thompson JF,. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003; 98: 1223-1231.
13. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004; 22: 3668-3676.
14. Havener L,. Standards for Cancer Registries. Volume III: Standards for Completeness, Quality, Analysis and Management Data. Springfield, IL: North American Association of Central Cancer Registries; 2012.
15. Therneau TM, Grambsch PM,. Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag; 2000.
16. Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009; 41: 544-552.
17. Damsky WE, Curley DP, Santhanakrishnan M, et al. Beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 2011; 20: 741-754.
18. Liu W, Monahan KB, Pfefferle AD, et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell. 2012; 21: 751-764.
19. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012; 118: 4014-4023.
20. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008; 372: 117-126.